Search results for: 'prenatal and postnatal'
- Did you mean
- prenatal ad postnatal
- Related search terms
- AND (SELECT (CASE WHEN (3989=1399) THEN NULL ELSE CTXSYS.DRITHSX.SN(1,3989) END) FROM DUAL) IS NULL
- AND (SELECT (CASE WHEN (4327=4327) THEN NULL ELSE CTXSYS.DRITHSX.SN(1,4327) END) FROM DUAL) IS NULL
- AND (SELECT (CASE WHEN (1509=3753) THEN NULL ELSE CTXSYS.DRITHSX.SN(1,1509) END) FROM DUAL) IS NULL-- wUvH
- AND (SELECT 1827 FROM (SELECT(SLEEP(20)))zydf)
- android edg pos terminals forecast 2024
-
12 Aug 2021  |  North America  |  Frost Radar
Frost Radar™: Non-Invasive Prenatal Testing, Global, 2021
A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines
Non-invasive prenatal testing (NIPT) provides an alternative to invasive, higher-risk tests such as amniocentesis, requiring a maternal blood sample to obtain cell-free DNA from both mother and fetus for analysis. Since NIPTs debut in 2011, laboratories and testing companies have made incremental upgrades to their non-invasive screens, improving ac...
$4,950.00
Special Price $3,712.50 save 25 %
-
12 Sep 2016  |  North America  |  Market Research
Price Point Analysis for Laboratory Developed Tests (LDTs) and FDA Regulated Tests
Discover the Perfect Assay Price Point to Remain Competitive
The main objective of this research is to estimate test volumes and unit prices for a wide variety of LDTs (genetic) and a few high volume FDA tests for selective therapeutic areas. The tests are categorized by their intended uses across the diagnostic spectrum (risk assessment, screening, diagnosis, staging and prognosis, therapy selection, therap...
$1,500.00
Special Price $1,125.00 save 25 %
-
05 Oct 2018  |  North America  |  Market Research
Growth Opportunities in the Global Liquid Biopsy Market, 2018
Companies are Vying for a Higher Market Position in the Early Cancer Screening Market
Liquid biopsy (CTCs and ctDNAs) is slowly gaining momentum in clinical care given its advantages over the traditional tissue-based gold standard methods. Short-term applications in cancer care range from risk assessment to cancer recurrence monitoring. Despite the proven advantages, there is still a significant number of barriers to adoption such a...
$4,950.00
Special Price $3,712.50 save 25 %
-
30 Jun 2021  |  North America  |  Market Research
US & EU Direct-to-consumer Genetic Testing Market, Key Trends & Growth Opportunities
Telegenetic Counseling to Revolutionize Access to Patient Care
In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...
$2,450.00
Special Price $1,837.50 save 25 %